Scarlet Therapeutics has entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to advance the development of smart red blood cells (SRBCs). Scarlet will lead a multidisciplinary consortium to develop SRBCs in a programme worth up to $14 million. The agreement builds on the company’s ability to engineer red blood cells to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!